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This study attempted to prepare polyethylene-glycol modified (PEGylated) and folate-PEGylated liposomes containing paclitaxel
(Ptx) in order to reduce the toxicity and improve the bioavailability and biocompatibility by targeting drugs to the lymphatics using
cancer cell specific ligand folate to prevent metastasis via the lymphatic system. Liposomes were prepared by lipid film hydration
method using PEG and folate-PEG as surface modifiers. The mean particle size and encapsulation efficiency of liposomes were
114± 6.81 nm and 81± 2.3% for PEGylated liposome and 122± 4.87 nm and 88± 2.0% for folate-PEGylated liposome, respectively.
According to stability test, it could be confirmed that PEGylated and folate-PEGylated liposomes were stable for at least 5 days. After
intravenous administration of the PEGylated and folate-PEGylated liposomes to rats, the CL
𝑡
(total clearance) and 𝑡
1/2
(half-life)
were significantly different (𝑃 < 0.05) compared with those of PADEXOL Inj. In targeting efficiency, calculated as the concentration
ratio of Ptx in lymph nodes and plasma, there was significant increase in targeting efficiency at lymph nodes (𝑃 < 0.05). From these
results, we could conclude that the prepared Ptx-containing PEGylated and folate-PEGylated liposomes are good candidates for
the targeted delivery of the drug to lymphatic system.
1. Introduction
Paclitaxel is an anticancer drug that has a diterpenoid







, corresponding to molecular weight of 853Da
[1]. Its anticancer activity was detected in 1967 and its ther-
apeutic efficacy also includes ovarian, breast, head, and neck
cancer, small lung cancer, colon cancer, multiple myeloma,
melanoma, and Kaposi’s sarcoma. The target of Ptx is micro-
tubules, which are polymeric intracellular structures com-
posed of chains of the dimeric protein tubulin [2, 3].However,
there are two limitations for clinical application of Ptx. One
is its low bioavailability (BA). Ptx is the substrate of P-gly-
coprotein (P-gp) [4]. The presence of this phenotype results
in a decreased accumulation of drug within the cancer cell,
which occurs by an increase in P-gp that functions as a drug
efflux pump [4, 5]. Another limitation of Ptx is its difficulty
in clinical administration. Ptx is highly hydrophobic (water
solubility ≤ 0.5mg/L). An adjuvant consisting of Cremophor
EL (polyoxyethylated castor oil) and dehydrated alcohol has
to be used in the current clinical administration of Ptx,
which causes serious side effects [6]. It has been believed that
side effects caused by Cremophor EL include hypersensitivity
reactions, nephrotoxicity, and neurotoxicity [7]. It was also
reported that Cremophor EL has influence on the functions
of endothelial and vascular muscle and causes vasodilation,
laboured breathing, lethargy, and hypotension [8].
Various formulations to increase BA of Ptx and reduce
these side effects of Cremophor EL were studied and devel-
oped. For example, liposome [9, 10], prodrug [11], micro-
sphere [12, 13], nanosphere [14, 15], self-emulsifying drug
delivery systems [16], nanoparticle [17, 18], nanosponge [19,
20], and combination with P-gp inhibitors [5, 21] were devel-
oped and evaluated. Among these formulations, nanoparti-
cles (NPs) are stable, solid colloidal particles consisting of bio-
degradable polymer or lipid materials and range in size
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from 10 to 1,000 nm. Drugs can be absorbed onto the part-
icle surface and are entrapped inside the polymer/lipid or
dissolvedwithin the particlematrix [22, 23].Over the past few
decades, there have been considerable interests in developing
nanosized liposomes as potential and effective drug delivery
carriers due to their ability to control drug release and
delivery. They can effectively deliver the drug to target sites
and thus increase the therapeutic benefit while minimizing
side effects [24, 25]. Moreover, surface-modified PEGylated
liposomes have been found to be important in potential
therapeutic applications as injectable colloidal systems for
controlled drug release with long circulation in the blood
[26, 27].
The folate receptor (FR) has been recognized as playing
a potential physiological role in cellular folate uptake. FRs
are overexpressed in cancer cells, especially ovarian cancers
[28–31]. A number of FR-targeted therapeutic and imaging
agents have been evaluated in preclinical studies including
liposomal agents [32–36]. Liposomes are taken up by kappa B
cells, which are highly concentrated in lymphatic fluid, specif-
ically compared with nontargeted liposomes [37]. Given the
high level of FR expression in ovarian carcinomas and the
effectiveness of Ptx as a first-line agent for this type of cancer
and preventing its metastasis via the lymphatic system, there
is good reason to develop an FR-targeted formulation for Ptx.
Manymethods have been used in the preparation of lipo-
somes. Among them, we selected the thin lipid film hydration
methodwith sonication and amodification [38] because of its
simplicity and reproducibility. In this study, we prepared and
characterized the PEGylated and folate-PEGylated liposomes
containing Ptx using the thin lipid film hydration method
with sonication to increase the time it circulated in the blood
and lymphatic delivery. We also evaluated pharmacokinetic
characteristics and lymphatic targeting efficiency of these
formulations in rats and the results were compared to those
of commercial product, PADEXOL Inj. for intravenous (i.v.)
administration.
2. Materials and Methods
2.1. Materials
2.1.1. Reagents. Ptx was kindly supplied by Dong Wha
Pharm. Co., Ltd. (Seoul, Korea). Glimepiride was kindly sup-
plied by Sam Chun Dang Pharm. Co., Ltd. (Seoul, Korea).
PADEXOL Inj. was formulated in Acephorol 330 as a
solubilizer and kindly supplied by Shin Poong Pharm. Co.,
Ltd. (Seoul, Korea). Egg-phosphatidylcholine (EPC), choles-
terol (CHOL), pyridine, dimethyl sulfoxide (DMSO), and
folic acid were purchased from Sigma Chemical Co. (St.




PEG-DSPE) were purchased from Avanti Polar Lipids Inc.
(Alabaster, Al, USA). N,N󸀠-dicyclohexylcarbodiimide
(DCC) was purchased from Fluka (Buchs, Switzerland).
Heparin sodium (25,000 IU/5mL, Green Cross, Seoul,
Korea) and phosphate buffered saline (PBS, pH 7.4, Sigma
Chemical Co., St. Louis, MO, USA) were used. Acetonitrile
(Fischer Scientific., Fair Lawn, NJ, USA) was used for HPLC
assay. HPLC grade water was obtained from a Milli-Q water
purification system (Millipore Co., Milford, MA, USA) and
was used throughout the study. Dialysis tubing cellulose
membrane ofmolecularweight cut-off (MWCO) 1,000 (Spec-
tra/Por CE, Spectrum laboratories Inc., Rancho Domingues,
CA, USA) was used for synthesis of folate-PEG and MWCO
12,000 (Sigma-Aldrich Co., St. Louis, MO, USA) was used
for the in vitro release test. All other chemicals and solvents
were of analytical grade or highest quality available.
2.1.2. Instruments. Homogenizer (IKA-WERKE,KGD-79219,
GmbH & Co., Staufen, Germany), tip-type ultrasonicator
(US-50, Nihonseiji Kalsha Ltd., Danbury, CT, USA), and
ultraspeed centrifuge (Centrikon T-2070, Kontron, Switzer-
land) were used for synthesizing folate-PEG and preparation
of liposomes. Particle size analyzer (Autosizer Lo-C, Malvern
Instruments, Worcesterahire, UK), zeta potential analyzer
(ELS-8000, Otsuka Electronics, Osaka, Japan), FE-SEM (field
emission-scanning electronmicroscopy, S-4700,Hitachi Ltd.,
Tokyo, Japan), and TEM (transmission electron microscopy,
JEM-200 FXII, JEOL Ltd, Tokyo, Japan) were used for
evaluation of prepared liposomes. HPLC system (Shimadzu
Corp., Kyoto, Japan) consisted of pump (Model LC-10ADvp),
degasser (Model DGU-12A), UV detector (Model SPD-
10Avp), system controller (SCL-10ADvp), and Shim-Pack
CLC-ODS (M) 15CM column (4.6 × 150mm analytical
column, 5 𝜇m particle size).
2.1.3. Experimental Animal. Experimental animals were
managed according to a protocol approved by the Ethical
Review Committee on Experimental Animals of Chon-
nam National University, South Korea. Eight-week-old male
Sprague-Dawley rats weighing 190∼210 g were obtained from
Dae Han Laboratory Animal Research Center Co., Ltd.
(Daejeon, Korea). Animals were housed separately in cages in
a ventilated animal room with controlled temperature (19 ±
1
∘C) and relative humidity (50 ± 5%) and kept on 12 hours
light/dark cycle. The rats weighing 240∼280 g were used.
2.2. Methods
2.2.1. Synthesis of Folate-PEG-DSPE. Folate-PEG-DSPE was
synthesized as previously reported [36, 37, 39]. In brief, 25mg
of folic acid was dissolved in 1mL of DMSO and 100mg of
amino-PEG-DSPE dissolved in 0.5mL of pyridine containing
32.5mg of DCC was added. The reaction mixture was left
to stand at room temperature for 4 hours and pyridine was
removed by rotary vacuum evaporation. Three milliliters of
water was added to the reaction mixture and the insoluble
materials were removed by centrifugation at 36,000 g for
15 minutes (Centrikon T-2070, Kontron, Switzerland). The
supernatant was dialyzed in Spectra/Por CE against saline for
24 hours and then against water for 24 hours. The dialyzed
product (folate-PEG-DSPE) was lyophilized and stored at
−20∘C before use.
2.2.2. Preparation of PEGylated and Folate-PEGylated Lip-
osomes. The PEGylated and folate-PEGylated liposomes
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containing Ptx were prepared with a modification of the thin
lipid film hydration method [38]. In detail, a mixture of EPC,
CHOL,DSPE-mPEG, folate-PEG-DSPE, and Ptx dissolved in
chloroform :methanol = 2 : 1 (v/v) was evaporated to dryness
by rotary vacuum evaporator under reduced pressure at
45∘C. A thin film was deposited on the inner wall of a
Quickfit 50mL round bottom glass flask. The dried lipid
film was dispersed by gentle rotation at room temperature
in pH 7.4 PBS solution. The resulting liposome dispersion
(about 20mM total lipid) was gently shaken and sonicated
for 10 minutes. Liposomes were centrifuged for 15 minutes
(50,000 g, 15∘C) in order to remove nonencapsulated Ptx
and multilamellar vehicles (MLV). Prepared liposomes were
filtered using a 450 nm polyvinylidenedifluoride (PVDF)
filter to remove large liposomes. The final liposomes in pH
7.4 PBS solution were stored at 4∘C until later use.
(1) Determination of Optimal Concentration of DSPE-mPEG.
EPC : CHOL : Ptx was fixed to 20 : 10 : 1 molar ratio. DSPE-
mPEGwas added to thismixture at concentrations of 0, 1, 2, 3,
and 4 molar ratio. The final lipid concentration was adjusted
to 20mM. Liposomes were prepared as previously described.
The optimal concentration of DSPE-mPEG was determined
from the results of particle size and drug encapsulation
efficiency (EE) of prepared liposomes.
(2) Determination of Optimal Concentration of Folate-PEG-
DSPE. EPC : CHOL : Ptx was fixed to a 20 : 10 : 1 molar ratio.
Folate-PEG-DSPE was added to this mixture at concentra-
tions of 0, 1, 2, 3, and 4 molar ratio. The final lipid concen-
tration was adjusted to 20mM. Liposomes were prepared as
previously described. The optimal concentration of DSPE-
mPEG was determined from the results of particle size and
EE of prepared liposome.
2.2.3. Characterization of PEGylated and
Folate-PEGylated Liposomes
(1) Determination of Particle Size of Liposomes. The mean
particle size and size distribution analysis of liposomes were
performed by the dynamic light scattering (DLS) method
at 25∘C with a 90∘ scattering angle for optimum detection.
One milliliter of the liposome dispersions was diluted with
5mL of filtered PBS (pH 7.4) using a polycarbonate filter
(0.1 𝜇mpore size,Milipore, UK) and the size of liposomeswas
measured immediately. The presented results (mean ± S.D.)
are representatives of five independent experiments.
(2) Determination of Drug Encapsulation Efficiency. Drug
concentrations were determined by reversed-phase HPLC.
One hundred microliters of PEGylated and folate-PEGylated
liposomes were mixed with 0.9mL of methanol and vortexed
vigorously for 1 minute. The solution was then diluted with
a specific volume of mobile phase and injected into HPLC.
The chromatographic column was Shim-Pack CLC-ODS
(M) 15CM reversed-phase column (4.6 × 150mm analytical
column, 5 𝜇m particle size). The mobile phase consisted
of acetonitrile : water (50 : 50, v/v) and the flow rate was
1mL/min. The quantity of Ptx was measured by the UV






weight of drug in liposome
weight of drug used in preparation of liposome
× 100.
(1)
(3) Measurement of Zeta Potential of Liposomes. The zeta
potential of prepared liposomes was measured by the ELS-
8000 zeta potential analyzer among different batches to assess
the surface charge and the stability of the liposomes. Zeta
potential of liposomes was measured in aqueous dispersion
(PBS, pH 7.4). The presented results (mean ± S.D.) are
representatives of independent experiments (𝑛 = 5).
(4) Morphological Characterization
(A) Scanning Electron Microscopic (SEM) Observation. The
morphology of PEGylated and folate-PEGylated liposomes
was observed using field-emission SEM. The PEGylated
liposome samples were coated with platinum (∼20 nm thick)
using an ion sputter (JFC-1100, JEOL Ltd., Tokyo, Japan)
for 5 minutes at 20mA. Observation was performed at an
accelerating voltage of 5 kV and a working distance of 10mm.
The SEM images were photographed at 10,000x and 50,000x,
respectively.
(B) Transmission Electron Microscopic (TEM) Observation. A
drop of PEGylated and folate-PEGylated liposomal solution
containing 1% of phosphotungstic acid (pH 7.0 adjusted with
1M KOH solution) was placed on carbon film coated on a
copper grid for TEM. Observation was performed at 80 kV
in a JEM-2000 FXII. The TEM images were photographed at
50,000x and 100,000x, respectively.
(5) Stability Test at Storage Condition. The stability of lipo-
somes in pH 7.4 PBS solution at storage conditions was
determined by changes in particle size and EE over a 5-day
period during storage at 4∘C. Samples were taken at different
time intervals over 24 hours and particle size and EE were
obtained immediately. The size of each sample was measured
by the particle size analyzer and EE was measured by HPLC
assay. Each experiment was repeated at least five times.
(6) In Vitro Release Study. For the in vitro release test of
Ptx from PADEXOL Inj., PEGylated liposomes and folate-
PEGylated liposomes at pH 7.4 phosphate buffermediumwas
prepared by the dialysismethod. Each preparation containing
Ptx was diluted with medium and the final concentration
of Ptx was adjusted to 90 𝜇g/mL. Each sample was put into
a dialysis tube (MWCO: 12,000) which was placed into a
50mL screw-capped Falcon tube with 10mL of dissolution
medium.The Falcon tubes were incubated in a shaking water
bath thermostated at 37∘C and shaken at a rate of 100 opm.
We changed whole media for new media to prevent drug
saturation after gathering samples of dissolution media. At
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the predetermined time intervals (3, 6, 12, 24, 48, 72, 120,
144, 168, 192, and 240 hours after starting incubation), whole
medium (10mL) was taken and replaced with the same
volume of fresh medium (10mL).The amount of Ptx released
was determined by HPLC.
(7) In Vivo Study. The femoral vein and artery were can-
nulated with a polyethylene tube (PE-50, Intramedic, Clay
Adams Co., Parsippany, NJ, USA) under light ether anes-
thesia. Cannulated rats were kept in restraining cages under
normal housing conditions for 1∼2 hours until they recovered
from anesthesia prior to the experiments. The rats were
divided into three groups (five animals in each group),
(1) PADEXOL Inj., commercial i.v. injection of Ptx, (2)
PEGylated liposomes containing Ptx for i.v. administration,
and (3) folate-PEGylated liposomes containing Ptx for i.v.
administration. A single dose (5mg/kg as Ptx) of each Ptx
formulation was given to rats intravenously at the same time
[40]. At predetermined time intervals (0.083, 0.25, 0.5, 0.75, 1,
2, 4, 6, 8, and 12 hours), whole blood samples (about 350 𝜇L)
were withdrawn via the femoral artery into a Vacutainer
tubewith EDTA.After immediate centrifugation (10,000 g, 10
minutes), the plasma was taken and stored at 4∘C until it was
assayed within 24 hours. Whole blood (approximately 1mL)
collected from untreated rats was infused via the femoral
artery at 0.5, 2, and 8 hours to replace blood-loss due to blood
sampling. Also, in order to evaluate the lymphatic delivery of
Ptx, the rats were also divided into three groups (five animals
in each group) and administered each formulation as men-
tioned above. At 4 hours after administration, whole blood
samples were taken via the abdominal aorta and centrifuged
immediately (10,000 g, 10 minutes), and lymph nodes such
as mesenteric and axillary lymph node were isolated and
weighed (25mg for each lymph node). These lymph node
samples were suspended by a homogenizer for 1 minute in
PBS (pH 7.4) to achieve a final concentration of 25mg/mL in
the homogenate and stored at −80∘C until being assayed.
(8) Determination of Ptx in Rat Plasma and Lymph Node Sus-
pension. The plasma concentrations of Ptx were determined
by HPLC assay and modification of the method reported
previously [41–43]. The HPLC conditions for the determi-
nation of Ptx in rat plasma and lymph node suspension
are the same as mentioned above ((2) determination of
drug encapsulation efficiency). The stock solutions of Ptx
(1mg/mL) were prepared in methanol and stored at 4∘C.
The stock solution of glimepiride (100 𝜇g/mL) for internal
standard (I.S.) was prepared by dissolving glimepiride in
ethanol. The calibration curves were obtained by plotting the
peak-area ratios of the drug to I.S. versus the concentration
of Ptx. Calibration standards at rat plasma and lymph node
suspension of Ptx were prepared at concentrations of 10, 20,
50, 100, 200, 500, 1000, and 10000 ng/mL in drug-free pooled
rat plasma and lymph node suspension. Briefly, 100 𝜇L of rat
plasma or lymph node suspension sample was put into a test
tube and 10 𝜇L of I.S. (glimepiride in ethanol diluted with
deionized water at a concentration of 5𝜇g/mL) was added.
After vortexing for 30 seconds, 2mL of dichloromethane
was added and vortexed for 2 minutes. The extract was then
centrifuged for 10 minutes at 10,000 g (4∘C). After aspirating
the upper layer, 1.5mL of the lower layer was transferred to
the new test tube for centrifugal evaporation for 1.5 hours
at 20,000 g at 45∘C under nitrogen stream. The residue was
reconstituted with 100 𝜇L of mobile phase by vortexing for
30 seconds and 50 𝜇L of the supernatant was injected into
the HPLC system.The intra- and inter-day assay precision as
well as the accuracy fulfilled the FDA guidelines [44], and the
mean absolute recoveries from plasma and lymph node were
95.4 ± 3.7 and 96.8 ± 4.7%, respectively.These results support
the idea that this method was applicable to the kinetics of Ptx
for plasma and lymph node suspension.
(9) Pharmacokinetic Analysis and Lymphatic Delivery Eval-
uation. The pharmacokinetic parameters associated with
i.v. administration were estimated by noncompartmental
methods using WinNonlin program [45]. The Ptx pharma-





from standard equations [46]. 𝐶max was directly obtained by
observation. The targeting efficiency of Ptx to the lymphatic
system was calculated as the ratio of Ptx concentration
in lymph nodes (mesenteric and axillary nodes) to the
concentration in rat plasma at 4 hours after i.v. administration
of each formulation.
2.2.4. Statistical Evaluation. All calculated values were
expressed as their mean ± S.D. All data were analyzed for
statistical significance by Student’s 𝑡-test with 𝑃 < 0.05 indi-
cating a significant difference.
3. Results and Discussion
3.1. Preparation of PEGylated and Folate-PEGylated Liposomes
3.1.1. Determination of Optimal Concentration of DSPE-
mPEG. EPC : CHOL : Ptx mixture was used with 20 : 10 : 1
molar ratio. The concentrations of DSPE-mPEG were varied
from 0 to 4 molar ratio with respect to the amount of modi-
fier in the liposome composition. When encapsulated in
the appropriated concentrations of DSPE-mPEG, DSPE-
mPEGhas been shown to increase encapsulation efficacy [47]
and to reduce the leakage of encapsulated drugs [48]. Our
results showed that the encapsulation efficiency was found to
increase between 0 and 3 molar ratio of DSPE-mPEG. But
little change was observed at 4 molar ratio. Also, liposomal
size was decreased with increasing DSPE-mPEGmolar ratio,
but there is not a remarkable difference between 3 and 4
molar ratio. The liposomal size was 114 ± 6.81 nm and EE was
81 ± 2.3%. From these results, the optimal concentration was
determined at 3 molar ratio of DSPE-mPEG (Table 1).
3.1.2. Determination of Optimal Concentration of Folate-
PEG-DSPE. We also determined the optimal molar ratio of
folate-PEG-DSPE. EPC : CHOL : Ptxmixture (20 : 10 : 1 molar
ratio) was used. The concentrations of folate-PEG-DSPE
(DSPE-mPEG : folate-PEG-DSPE = 9 : 1) varied from 0 to 4
molar ratio with respect to the amount of modifier in the
liposome composition. Our results showed that the encap-
sulation efficiency increased between 0 and 3 molar ratio of
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Table 1: Change of liposomal size and drug EE of PEGylated and folate-PEGylated liposomes containing Ptx various molar ratios of DSPE-
mPEG#.
Molar ratio of DSPE-mPEG Liposomal size (nm) Encapsulation efficiency (%)
PEGylated liposome Folate-PEGylated liposome PEGylated liposome Folate-PEGylated liposome
0 224 ± 21.8 224 ± 21.8 76 ± 1.8 76 ± 1.8
1 148 ± 3.65∗ 140 ± 9.79∗ 78 ± 3.6 77 ± 1.3
2 123 ± 10.2∗ 126 ± 6.65∗ 79 ± 2.7 82 ± 1.2∗
3 114 ± 6.81∗ 122 ± 4.87∗ 81 ± 2.3∗ 88 ± 2.0∗
4 121 ± 20.0∗ 125 ± 3.40∗ 83 ± 4.8∗ 68 ± 1.3∗
#Mean ± S.D. (𝑛 = 5). ∗𝑃 < 0.05 between 0 and specific molar ratio of DSPE-mPEG.
folate-PEG-DSPE, but little change was observed at 4 molar
ratio. Also, liposomal size decreased with increasing folate-
PEG-DSPE molar ratio, but there is not a remarkable differ-
ence between 3 and 4 molar ratio. The liposomal size was
122 ± 4.87 nm and EE was 88 ± 2.0%. We conclude that lipo-
somal size slightly increased (from 114 to 122 nm). Encapsula-
tion efficiency was also increased (from 81 to 88%) due to
the addition of folate to PEG-DSPE liposomes. From these
results, the optimal concentration was at 3 molar ratio of
folate-PEG-DSPE (Table 1).
3.1.3. Zeta Potential of PEGylated and Folate-PEGylated Lipo-
somes. Thezeta potential value is an important characteristic,
and it can influence liposome stability and mucoadhesion.
Our results of zeta potential were −27.7 ± 5.51 and −42.9 ±
6.28mV for PEGylated and folate-PEGylated liposomes,
respectively. Therefore, we expected that prepared liposomes
can increase the residence time of anticancer drugs in the
circulation, enhance drug accumulation in tumors, and be
well-distributed to other tissues [49].
3.2. Morphological Characterization of PEGylated and Folate-
PEGylated Liposomes. In the SEM observation (Figure 1),
the PEGylated and folate-PEGylated liposomes containing
Ptx prepared from above optimal conditions were about
100 nm in size and had a comparatively spherical shape with
a smooth surface, which were almost the same results in
the TEM observation (Figure 2) as well as DLS analyzer
measurements.These results have shown that PEGylated and
folate-PEGylated liposomes containing Ptx having a particle
size of about 100 nm and a nicemorphologywere successfully
prepared by this method.
3.3. Stability Test of Liposomes at StorageCondition. As shown
in Table 2, the particle size and EE of both PEGylated and
folate-PEGylated liposomes in pH 7.4 PBS solution were
insignificantly (𝑃 > 0.05) changed during 5 days. But EE
had tendency to be slightly decreased as time went by. We
considered that this result was due to the release of Ptx which
was attached to the surface of the liposomes.We think that the
liposomal formulations showed excellent colloidal stability
and drug retention during this period. And there were no
visible changes to the physical appearance of the formulation
or signs of drug precipitation. The results showed that the
prepared liposomes in pH 7.4 PBS solution were stable at least
for 5 days at storage conditions (4∘C).
3.4. In Vitro Release Study. Figure 3 compares the release
profiles of Ptx from PADEXOL Inj., PEGylated liposomes,
and folate-PEGylated liposomes in pH 7.4 phosphate buffer
medium. The release profiles between PEGylated and folate-
PEGylated liposomes containing Ptx were similar and
showed significantly lower profiles than PADEXOL Inj. (𝑃 <
0.05).The average release ratio of folate-PEGylated liposomes
tended to be relatively small compared to that of PEGylated
liposomes. This result is likely due to the addition of folate to
PEGylated liposomes. Therefore, the PEGylated and folate-
PEGylated liposomes containing Ptx have a potential appli-
cation for controlled release into the blood and lymphatic
system.
3.5. Pharmacokinetic Analysis and Lymphatic Targeting Effi-
ciency Evaluation. Figure 4 shows the mean concentration-
time profiles of Ptx in rat plasma after i.v. administration
of PADEXOL Inj., PEGylated liposome containing Ptx, and
folate-PEGylated liposomes containing Ptx (5mg/kg as Ptx)
(𝑛 = 5). Table 3 lists the pharmacokinetic parameters
obtained by the noncompartmental method using WinNon-




, and𝐶max of PEGylated
and folate-PEGylated liposomes containing Ptx were signifi-
cantly different (𝑃 < 0.05) from those of PADEXOL Inj. The
𝑡
1/2
of the prepared liposomes was about three times higher
than that of PADEXOL Inj. and the CL
𝑡
was about three times
lower than that of PADEXOL Inj. These results showed that
the prepared liposomes circulated in the blood for a longer
period of time and were consistent with the expectation from
the in vitro release study. The pharmacokinetic parameters
of Ptx reported that the 𝑡
1/2
was 2.3 hours and the CL
𝑡
was
775mL/hr⋅kg at the i.v. dose of 5mg/kg [50]. In a previously
related study, the CL
𝑡
of paclitaxel solution at the i.v. dose of
7.5mg/kg was 1677.85mL/hr⋅kg [51]. Based on these results,
we conclude that the CL
𝑡
in our study is comparable with that
in related studies. The concentrations of Ptx in mesenteric
and axillary lymphnodes after i.v. administrationwere shown
in Table 3. There was a significant difference between the
prepared liposomes containing Ptx and control formulation
(PADEXOL Inj.) (𝑃 < 0.05). In the case of PEGylated and
folate-PEGylated liposomes, the concentration of Ptx in the
lymph nodes was lower compared to the control formulation.
The observed difference in these data could be related to the
difference in their biocompatibility. A large number of lym-
phocytes, such as macrophages or leukocytes, are known to
be distributed in the lymph nodes and lymphatic capillaries.
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(a) (b)
Figure 1: SEM image of (a) PEGylated liposomes containing Ptx (70,000x) and (b) folate-PEGylated liposomes containing Ptx (100,000x).
(a) (b)
Figure 2: TEM image of (a) PEGylated liposomes containing Ptx (bar = 100 nm) and (b) folate-PEGylated liposomes containing Ptx (bar =
100 nm).
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Figure 3: In vitro release profiles of Ptx from PADEXOL Inj. (∙), PEGylated liposomes (◼), and folate-PEGylated liposomes (󳵳) in dissolution
media (pH 7.4). Each value represents the mean ± S.D. (𝑛 = 5). ∗𝑃 < 0.05 between PADEXOL Inj. and the prepared liposomes.
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Table 2: The changes of liposomal size and encapsulation efficiency of PEGylated and folate-PEGylated liposomes at 4∘C for 120 hours#.
Time (hour) Liposomal size (nm) Encapsulation efficiency (%)
PEGylated liposome Folate-PEGylated liposome PEGylated liposome Folate-PEGylated liposome
0 114 ± 6.81 122 ± 4.87 81 ± 2.3 88 ± 2.0
24 115 ± 4.26 128 ± 5.02 81 ± 2.0 86 ± 1.3
48 115 ± 2.57 128 ± 4.38 80 ± 3.5 88 ± 1.4
72 114 ± 3.91 129 ± 4.26 80 ± 3.1 86 ± 1.8
96 115 ± 4.44 129 ± 4.24 79 ± 3.0 86 ± 1.1
120 115 ± 2.71 128 ± 6.84 79 ± 1.8 85 ± 2.5
#Mean ± S.D. (𝑛 = 5).
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Figure 4: Mean plasma concentration-time curves of Ptx after i.v. administration (5mg/kg) of PADEXOL Inj. (∙), PEGylated liposomes
containing Ptx (◼), and folate-PEGylated liposomes containing Ptx (󳵳) to rats. Each value represents the mean ± S.D. (𝑛 = 5). ∗𝑃 < 0.05
between PADEXOL Inj. and the prepared liposomes.
Thus, although the blood concentrations of Ptx in the pre-
pared liposomes at 4 hours after i.v. administration (5mg/kg)
to rats were significant (𝑃 < 0.05) lower than those in the
control formulation (PADEXOL Inj.), on the contrary, the
relative delivered effects of Ptx in the prepared liposomes
on both lymph nodes compared to the control formulation
increased due to their biocompatibility, phagocytosis by
enriched macrophages, and so on.
Lymphatic targeting efficiency of Ptx into the mesenteric
and axillary lymph nodes was shown in Table 3. After i.v.
administration, the lymphatic targeting efficiency of PEGy-
lated and folate-PEGylated liposomes containing Ptx was sig-
nificantly increased when compared with that of PADEXOL
Inj. (𝑃 < 0.05) in both lymph nodes.This increased lymphatic
targeting efficiency can lower the drug concentration needed
to have an effect. Delivering with the prepared liposomes
increased not only the time of the drug circulation but also
it seems to increase the efficacy at the target sites and reduce
the systemic side effects as we expected.These results suggest
that PEGylated and folate-PEGylated liposomes containing
Ptx could be as effective for targeting delivery of Ptx to the
lymphatic system as the i.v. formulation.
4. Conclusions
The PEGylated and folate-PEGylated liposomes containing
Ptx with diameters of about 120 nm could be prepared easily
and are reproducible by lipid film hydration method. The
drug EE was above 80% at the optimal molar ratio. From




of the prepared liposomes
were significantly different from those of PADEXOL Inj. (𝑃 <
0.05). The prepared liposomes showed significantly higher
lymphatic targeting efficiency than that of PADEXOL Inj.
at the mesenteric and axillary lymph nodes (𝑃 < 0.05).
Generally, most of the nanosized prepared liposomes accu-
mulate to the target lymph node during continuous systemic
circulation due to the physicochemical characteristics such as
particle size and biodegradable polymers coating the surface.
The prepared liposomes can easily pass through the walls
of lymphatic capillaries during systemic circulation, and this
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Table 3: Pharmacokinetic parameters and targeting efficiencies of Ptx to mesenteric and axillary lymph nodes at 4 hours after i.v.
administration (5mg/kg) of the prepared PEGylated and folate-PEGylated liposomes containing Ptx and PADEXOL Inj. to rats#.
Parameters PADEXOL Inj. PEGylated liposome Folate-PEGylated liposome
𝑡
1/2
(hour) 3.43 ± 1.35 10.8 ± 3.51∗ 9.14 ± 2.26∗
CL
𝑡
(mL/hr⋅kg) 1285 ± 317.0 413.5 ± 106.1∗ 380.3 ± 115.7∗
𝐶max (𝜇g/mL) 5.16 ± 1.30 37.5 ± 7.47
∗ 51.4 ± 12.3∗
Concentration (ng/g lymph node)
Mesenteric lymph node 1364 ± 102.2 740.0 ± 236.1∗ 810.4 ± 247.0∗
Axillary lymph node 1304 ± 112.7 672.8 ± 182.1∗ 712.3 ± 102.4∗
Targeting efficiency
Mesenteric lymph node 8.06 ± 1.04 15.1 ± 4.14∗ 18.8 ± 4.81∗
Axillary lymph node 8.01 ± 1.11 13.9 ± 2.98∗ 16.6 ± 3.18∗
#Mean ± S.D. (𝑛 = 5). ∗𝑃 < 0.05 between PADEXOL Inj. and the prepared liposomes.
passive targeting enables the drug to be targeted to the lym-
phatic system. Based on the results of our study, we conclude
that this mechanism is related to the drug delivery system
of the prepared liposomes. Therefore, it was suggested that
the prepared liposomes have an effect on targeting Ptx to the
lymph node, and the prepared liposomes are good candidates
for delivering Ptx to the lymphatic system.
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